Cassava Sciences (NASDAQ: SAVA) is a clinical-stage biotech company developing simufilam for the treatment of Alzheimer’s disease. For a while, the market thought highly of Cassava’s prospects.

Cassava (NASDAQ: SAVA) has been at the center of significant controversy and speculation within the biopharmaceutical sector, particularly around its Alzheimer’s treatment candidate, Simufilam.

Sava has revealed plans for an ambitious renovation of a moldy old retail building in Vietnam. The project will be focused on increasing light and views inside and will be fronted by an eye ...

Cassava Sciences (SAVA) announced that the Company presented a poster at the TSC International Research Conference held June 26-28, 2025 in ...

We suggest a strategy for new management. Read here for a discussion on the cautionary tale from ANVS for trading Cassava Sciences' Alzheimer's drug readout.

Cassava (SAVA) made positive progress with simufilam, an oral drug treatment for Alzheimer's disease dementia. The company's shares gain in the last month.

In this Sava Sound Pod review, I detail my experience trying out the immersive sound therapy pod that aims to improve sleep and stress.

The heavy selling pressure might have exhausted for Cassava Sciences (SAVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall ...

So, what is the takeaway from these latest developments with SAVA? Is it time to bail on the stock, or does this remain a worthwhile opportunity for aggressive investors?

Adding to challenges in drug development, SAVA faces scrutiny over data integrity issues. Accusations have targeted its co-founder for skewing test results to favor Simufilam.